Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Yan-Wei Ye"'
Autor:
Tao Liu1, Yan-Wei Ye1, A-li Zhu1, Zhen Yang1, Yang Fu1, Chong-Qing Wei1, Qi Liu1, Chun-Lin Zhao1, Guo-Jun Wang1, Xie-Fu Zhang1 zhangxiefu163@163.com
Publikováno v:
OncoTargets & Therapy. 2015, Vol. 8, p1265-1270. 6p.
Autor:
Jianghong Wu, Xiefu Zhang, Chunlin Zhao, Lin Yuan, Yan Wei Ye, Chunyan Du, Yingqiang Shi, Guojun Wang, Chunmeng Wang, Ye Zhou
Publikováno v:
Journal of Surgical Oncology. 106:872-879
Background Fibroblast growth factor receptor 4 (FGFR4) was seldom investigated in gastric cancer (GC). The purpose of the study was to elucidate the expression of FGFR4 protein in GC and related clinical significance. Methods Ninety-four paraffin-emb
Autor:
Yan Wei Ye, Ying Qiang Shi, Bi Qiang Zheng, Jiang Hong Wu, Xi Cao, Chun Meng Wang, Meng Hong Sun, Xiao Yan Zhou, Ye Zhou, Chun Yan Du
Publikováno v:
Cancer Letters. 307:124-131
Sox17, a transcription factor, was considered as an antagonist to inhibit canonical Wnt/β-catenin signaling in several malignant tumors. Extremely little is known about Sox17 in gastric cancer. Therefore, the aim of this study was to elucidate the v
Autor:
Yan Wei Ye, Chun Meng Wang, Xi Cao, Ying Qiang Shi, Lin Yuan, Chun Yan Du, Xiao Yan Zhou, Bi Qiang Zheng, Hong Fu, Ye Zhou, Meng Hong Sun
Publikováno v:
Cancer. 117:5304-5313
BACKGROUND: Fibroblast growth factor receptor 4 (FGFR4) belongs to the tyrosine kinase receptor family. Little is known about the effect of FGFR4 on gastric cancer (GC). Therefore, the objective of the current study was to elucidate the role of FGFR4
Publikováno v:
Journal of Surgical Oncology. 104:76-82
Background The aim of this study was firstly to elucidate the prognosis of familial gastric cancer (FGC) in Chinese population. Methods A total of 162 patients were recruited, including 81 patients with FGC and 81 patients with sporadic gastric cance
Autor:
Ye Zhou, Kai Huang, Chun Meng Wang, Chun Yan Du, Hong Fu, Yan wei Ye, Xiao Yan Zhou, Ying Qiang Shi
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 136:1065-1071
Most gastrointestinal stromal tumor (GIST) patients respond to KIT inhibition therapy of imatinib, but eventually become resistant with a median time to progression of 2 years. The mechanism of acquired resistance to imatinib and oncogenic KIT signal
Autor:
Jianguo Wen, Ye Zhou, Shuang Hu, Yan Wei Ye, Guojun Wang, Ying Qiang Shi, Chun Lin Zhao, Xie Fu Zhang, Hong Zong
Publikováno v:
Oncology reports. 30(6)
Our previous findings revealed that FGFR4 may be a novel therapeutic target for gastric cancer. The aim of the present study was to explore the effects of a combination of PD173074 (PD) and 5-fluorouracil (5-Fu) on the biological behavior of gastric
Autor:
Yan-Wei, Ye, Xiefu, Zhang, Ye, Zhou, Jianghong, Wu, Chunlin, Zhao, Lin, Yuan, Guojun, Wang, Chunyan, Du, Chunmeng, Wang, Yingqiang, Shi
Publikováno v:
Journal of surgical oncology. 106(7)
Fibroblast growth factor receptor 4 (FGFR4) was seldom investigated in gastric cancer (GC). The purpose of the study was to elucidate the expression of FGFR4 protein in GC and related clinical significance.Ninety-four paraffin-embedded tumor specimen
Autor:
Yan-Wei, Ye, Rui-Zheng, Dong, Ye, Zhou, Chun-Yan, Du, Chun-Meng, Wang, Hong, Fu, Ying-Qiang, Shi
Publikováno v:
Journal of surgical oncology. 104(1)
The aim of this study was firstly to elucidate the prognosis of familial gastric cancer (FGC) in Chinese population.A total of 162 patients were recruited, including 81 patients with FGC and 81 patients with sporadic gastric cancer (SGC), who underwe
Publikováno v:
Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery. 13(8)
To evaluate the clinicopathological characteristics and prognosis of poorly differentiated neuroendocrine carcinoma of the stomach.Twenty-three poorly differentiated neuroendocrine carcinomas of the stomach were treated in the Department of Abdominal